AVNS Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Avanos Medical Inc (AVNS) is not a strong buy at the moment given the investor's long-term strategy and beginner level. While the technical indicators show some bullish momentum, the financial performance is weak, with significant declines in net income, EPS, and gross margin. Additionally, there are no recent positive news catalysts or significant trading trends from insiders or hedge funds. The options data indicates low trading sentiment, and there are no strong signals from Intellectia Proprietary Trading Signals. For a long-term investor, it may be better to wait for clearer signs of financial recovery or stronger market sentiment before investing.
The technical indicators show some bullish momentum. The MACD is positively expanding, and the moving averages are bullish (SMA_5 > SMA_20 > SMA_200). The RSI is neutral at 63.46, and the stock is trading near its resistance level of 14.37. However, the overall trend does not indicate a strong breakout or significant upward momentum.
The stock has a 70% chance of gaining 1.69% in the next day, 4.06% in the next week, and 12.69% in the next month based on historical candlestick patterns. Analysts have raised the price target recently.
Weak financial performance in Q4 2025, with net income, EPS, and gross margin all significantly declining. No recent news, insider trading, or hedge fund activity to drive positive sentiment. Options data suggests low trading interest.
In Q4 2025, revenue increased slightly by 0.72% YoY to $180.9M. However, net income dropped drastically by 99.67% YoY to -$1.3M, EPS fell by 99.65% YoY to -0.03, and gross margin decreased by 12.88% YoY to 47.54%.
Barclays recently raised the price target on AVNS to $11 from $9 and maintained an Overweight rating. This indicates some optimism from analysts, but the price target remains below the current market price.
